Press coverage about AtriCure (NASDAQ:ATRC) has been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. AtriCure earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 45.5175104138136 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

AtriCure (NASDAQ:ATRC) opened at $18.44 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.28 and a quick ratio of 1.65. AtriCure has a twelve month low of $14.78 and a twelve month high of $25.18.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Wednesday, November 1st. The medical device company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.02. The business had revenue of $42.20 million during the quarter, compared to analyst estimates of $43.44 million. AtriCure had a negative return on equity of 20.28% and a negative net margin of 19.40%. The company’s quarterly revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.21) EPS. analysts predict that AtriCure will post -0.96 earnings per share for the current fiscal year.

A number of equities research analysts recently issued reports on ATRC shares. Zacks Investment Research cut AtriCure from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Piper Jaffray Companies restated a “buy” rating and issued a $24.00 price objective on shares of AtriCure in a research note on Sunday. TheStreet cut AtriCure from a “c-” rating to a “d+” rating in a research note on Wednesday, November 29th. ValuEngine cut AtriCure from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, Canaccord Genuity lowered their price objective on AtriCure from $28.00 to $24.00 and set a “buy” rating on the stock in a research note on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $24.67.

In related news, Director B Kristine Johnson bought 1,500 shares of AtriCure stock in a transaction on Wednesday, November 8th. The stock was acquired at an average price of $18.36 per share, with a total value of $27,540.00. Following the acquisition, the director now directly owns 10,969 shares of the company’s stock, valued at $201,390.84. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO M. Andrew Wade sold 2,000 shares of AtriCure stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $18.41, for a total value of $36,820.00. The disclosure for this sale can be found here. 11.90% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: “AtriCure (ATRC) Earns News Sentiment Score of 0.15” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/13/atricure-atrc-earns-news-sentiment-score-of-0-15.html.

AtriCure Company Profile

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Stock Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related stocks with our FREE daily email newsletter.